Brand name
Avmapki Fakzynja Co-Pack, the original
We didn’t find a savings card or cash price from Avmapki Fakzynja Co-Pack’s maker. Ask the pharmacy for Avmapki Fakzynja Co-Pack’s cash price. With insurance, ask what your plan charges.
Generic name: avutometinib and defactinib
Used for: Low-grade serous ovarian cancer that came back, with a KRAS mutation
Ask for the cash price
Avmapki Fakzynja Co-Pack
We didn’t find one.
Avmapki Fakzynja Co-Pack, the original
We didn’t find a savings card or cash price from Avmapki Fakzynja Co-Pack’s maker. Ask the pharmacy for Avmapki Fakzynja Co-Pack’s cash price. With insurance, ask what your plan charges.
There isn’t one.
We didn’t find one.
AVMAPKI FAKZYNJA CO-PACK, a combination of avutometinib and defactinib, each kinase inhibitors, is indicated for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Source: the FDA label for Avmapki Fakzynja Co-Pack (Verastem Inc.), May 1, 2025. Full label on DailyMed
Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/avmapki-fakzynja-co-pack/